Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Oakwood Laboratories LLC has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 2 distinct art units. This concentration in only two art units suggests that the company's applications are focused on specific technical sub-fields, even though they are being reviewed by different individuals. This structure may allow for some consistency in art unit-level policy while dealing with multiple examiners across the 2 distinct art units.
Tigabu Kassa is the busiest examiner for the portfolio, with 1 pending office action. Because there are several pending actions in total, the workload is distributed such that each examiner holds a portion of the cases, making Tigabu Kassa 1 of the examiners currently reviewing the company's applications. For the practitioner, this means that the action under Tigabu Kassa is just as critical as the others, as each examiner holds a share of the company's active prosecution workload. Managing these relationships requires a coordinated strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
| KIM, DANIELLE A | 1 | 36.6% | +51.9% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18467283 | MICROSPHERE FORMULATIONS COMPRISING NALTREXONE AND METHODS FOR MAKING AND USING THE SAME | ARNOLD, ERNST V | 2d overdue |
| 18756907 | MICROSPHERE FORMULATIONS COMPRISING KETAMINE AND METHODS FORMAKING AND USING THE SAME | KASSA, TIGABU | — |
| 18713417 | MICROSPHERE FORMULATIONS COMPRISING ASENAPINE AND METHODS FOR MAKING AND USING THE SAME | KIM, DANIELLE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18467283 | MICROSPHERE FORMULATIONS COMPRISING NALTREXONE AND METHODS FOR MAKING AND USING THE SAME | ARNOLD, ERNST V | 2d overdue |
| 18756907 | MICROSPHERE FORMULATIONS COMPRISING KETAMINE AND METHODS FORMAKING AND USING THE SAME | KASSA, TIGABU | — |
| 18713417 | MICROSPHERE FORMULATIONS COMPRISING ASENAPINE AND METHODS FOR MAKING AND USING THE SAME | KIM, DANIELLE A | — |
| 18674044 | MICROSPHERE FORMULATIONS COMPRISING LURASIDONE AND METHODS FOR MAKING AND USING THE SAME | BASQUILL, SEAN M | — |
| Art Unit | Apps |
|---|---|
| 1613 | 2 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18756907 | MICROSPHERE FORMULATIONS COMPRISING KETAMINE AND METHODS FORMAKING AND USING THE SAME | KASSA, TIGABU | — | §103§112Other | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18713417 | MICROSPHERE FORMULATIONS COMPRISING ASENAPINE AND METHODS FOR MAKING AND USING THE SAME | KIM, DANIELLE A | 1613 | §103§112 | Non-Final OA | — | Pending | May 24, 2024 |
| 18674044 | MICROSPHERE FORMULATIONS COMPRISING LURASIDONE AND METHODS FOR MAKING AND USING THE SAME | BASQUILL, SEAN M | 1614 | §103DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18467283 | MICROSPHERE FORMULATIONS COMPRISING NALTREXONE AND METHODS FOR MAKING AND USING THE SAME | ARNOLD, ERNST V | 1613 | §102§103§112 | Final Rejection | 2d overdue | Pending | Sep 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOakwood Laboratories LLC has 4 pending office actions as of October 2026, spread across 2 art units and 4 examiners.
Tigabu Kassa has the most, with 1 of Oakwood Laboratories LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
